Genes & biomarkers

ALK fusions and rearrangements

ALK · EML4-ALK

An ALK fusion joins ALK to another gene.

Sources checked · Introductory guide

On this page

What does this result mean?

ALK rearrangements can produce abnormal growth signals. An ALK fusion in lung cancer is not the same finding as an ALK point variant in another disease.[1]

How does it connect to treatment?

ALK-positive non-small cell lung cancer may be treated with inhibitors such as alectinib. The setting, including selected postoperative or metastatic disease, determines eligibility.[2]

What should I check in my report?

Ask whether the result is a fusion/rearrangement and how ALK positivity was established. If cancer progresses, review previous ALK drugs alongside any new test.

Questions for your care team

  • Which test established my ALK-positive result?
  • Which treatments or trials fit my cancer type, stage and previous treatment?

Sources and scope

Source documents are in English.

Entries summarize and translate linked official public sources. The source-check date records when those sources were checked; it does not indicate a clinician’s review.

  1. MedlinePlus Genetics · ALK (opens in a new tab)
  2. NCI · alectinib (opens in a new tab)

General information based on official public sources. This is not a complete list of uses or side effects. Individual treatment decisions require your care team and current source documents. US-source uses do not establish local approval or reimbursement.

Related entries

ALK fusions and rearrangements | Cancer Encyclopedia | My Chemo Diary